Cancer risk assessment involves the steps of hazard identi cation, dose-respons e assessment, exposure assessment, and risk characterization. The rapid advances in the use of molecular biology approache s has had an impact on all 4 components , but the greatest overall current and future impact will be on the dose-respons e assessment because this requires an understanding of the mechanisms of carcinogenesis , both backgroun d and induced by environmenta l agents. In this regard, hazard identi cation is a qualitative assessment and dose-respons e is a quantitative estimate. Thus, the latter will ultimately require a quantitative assessment of molecular endpoint s that are used to describe the dose-respons e for cancer. It has been possible for many years to quantitate alterations at the level of the single gene. For example, analysis of mutation frequency by phenotypic selection, analysis of transcription (mRNA) by Northern blot, analysis of translation (proteins) by Western blot, and analysis of kinetics of metabolism from metabolite levels. However, it is becoming clear that it is necessary when considering risk for adverse health outcomes to develop quantitative approache s for whole cell phenotype s or organ effects. For example, cancer is a whole tissue phenotype, not a feature of single gene mutations, in spite of the multistep (multimutation) mode of formation of a tumor. Thus, there is the need to quantitate the circuitry of a cell: the metabolic/biochemical pathways, genetic regulation pathways, and signaling pathways in normal and stressed conditions. The hypothesis presented by Hanahan and Weinberg of the requirement for 6 acquired characteristics for tumor development , independen t of tissue type and species or inducer, seems to provide a viable approach. This hypothesis can be addressed through whole cell molecular assessment using microarrays and quantitative PCR together with the emerging proteomic approaches . This is the world of the new computationa l cell biology.
INTRODUCTION
The cancer risk assessment paradigm as described by the National Academy of Sciences (NAS)/National Research Council (NRC) (22) consists of 3 related components: hazard identi cation, dose-response assessment, and exposure assessment. These 3 components together comprise risk characterization. Hazard identi cation is a purely qualitative descriptor, namely is a chemical a carcinogen (human or otherwise) or not. For cancer risk assessments, as conducted until fairly recently by the US Environmental Protection Agency (US EPA) (10) , this qualitative assessment was combined with experimental data and a set of uncertainty factors for extrapolating to frequency of cancer in humans at low exposure levels. More recently, in the US EPA Proposed Guidelines for Carcinogen Risk Assessment (11) , the use of mechanistic data in the form of mode-of-action was identi ed as being valuable in the description of the shape of the cancer doseresponse curve at low exposure levels. Estimated parameters based upon the mode-of-action can be used in the development of biologically based, dose-response models (20, 23) . By and large, an understanding of mode-of-action for a particular chemical or mixture will provide a qualitative assessment of the tumor dose-response curve. Mode-of-action describes one or more necessary steps in the pathway from a normal cell to a malignant one that are not by themselves suf cient to complete the process. A quantitative assessment requires the incorporation of de ned mechanistic data that itself can be quantitated. The types of mechanistic data that might t this bill are those for speci c cellular alterations that are involved in tumor formation and could be considered to be rate-limiting. This would appear to be a daunting task, but new approaches to our understanding of the process of carcinogenesis and to quantitating cellular alterations open the way to begin to address the development of truly quantitative cancer dose-response models.
MULTISTAGE CARCINOGENESIS
In general terms, even though our level of knowledge has increased very signi cantly over the past 30 years or so, the carcinogenic process is viewed as a multistage progression from a normal cell to a malignant tumor. This model has progressed from that originally described by Foulds (13) to that developed by Kinzler and Vogelstein (18) for colon cancer, in which speci c phenotypic stages are linked to genotypic alterations.
This latter version of the multistage model can be considered as representing an idealized template that is perhaps relevant for some tumors and for some proportion of cells in any 1 tumor, appreciating the clonal nature of tumors. Hanahan and Weinberg (14) present a different kind of template to help explain the wide range of tumor types and the wide range of genotypes among any 1 tumor type. It is this type of template, incorporating a set of acquired capabilities, that is extremely useful for viewing the mechanisms of carcinogenesis by both mutagenic and epigenetic chemicals. The aim of the model is to explain also how cells can overcome their inherent ability to protect against transformation. The 6 essential alterations or acquired capabilities presented 112 0192-6233/02$3.00 $0.00 in the Hanahan and Weinberg model are: self-suf ciency in growth signals (eg, activate H-ras oncogene); insensitivity to antigrowth signals (eg, lose retinoblastoma suppressor); evading apoptosis (eg, produce IGF survival factors); limitless replicative potential (eg, turn on telomerase); sustained angiogenesis (eg, produce VEGF inducer); tissue invasion; and metastasis (eg, inactivate E-cadherin). It is readily possible to view the various cellular processes that are induced or altered by mutagenic and epigenetic carcinogens within the framework of the Hanahan and Weinberg model. The order of these acquired capabilities can vary among and within tumor types, and the impact of a particular change can be quite variable depending on, for example, the cell type or the timing of the production of the alteration along the pathway.
An additional hallmark of cancer is the development of genomic instability, whereby tumor cells at some stage during their development, quite possibly early on, exhibit a broad range of karyotypic abnormalities (chromosomal structural and numerical alterations) along with gene mutations. The magnitude of this instability is clearly demonstrated by the study of Stoler et al (25) , who showed that colon carcinoma cells contained on the order of 11,000 genomic alterations. In addition, colorectal premalignant polyps early in the tumor progression pathway contained a similar number of alterations, supporting the view of genomic instability being an early event. This high level of genomic instability needs to be put in the context of the rather straightforward model of Kinzler and Vogelstein (18) with its 5 steps from a normal cell to a malignant one. It is clear that genomic instability is the driver of the process, be it some tumor-speci c number of steps or a compilation from the set of 6 acquired capabilities. The challenge within the context of this presentation is to establish criteria for quantitating genomic instability such that its impact on dose-response characterization can be assessed.
The impact of the acquired capability model of Hanahan and Weinberg (14) and the development of rampant genomic instability, from what could be a single mutation in a caretaker gene, on the shape of the dose-response curves for tumor induction will be considerable. It is prudent to begin to consider all tumor dose-response curves as being complex irrespective of whether a carcinogen is mutagenic or epigenetic. The following sections address, in a broad sense, the types of quantitative assessment of cellular alterations that are becoming available to aid in the development of mechanistically based carcinogen risk assessment models.
BIOMARKERS AND BIOINDICATORS
Biomarkers have been utilized for many years to indicate exposure in environmental and occupational settings. They have also, particularly for ionizing radiations, been used to estimate the magnitude of an exposure (2, 21) . In a parallel approach, biomarkers have also been used to estimate dose to a target tissue in animal studies and to a small extent in human studies (24) . These types of studies have provided information on the dose component of dose-response characterization for tumor induction from environmental exposures. The selection of even more informative biomarkers of exposure and dose is becoming feasible as more is learned about cellular responses at the DNA, RNA, and protein levels to exposure. The emphasis here is on selection of informative biomarkers from basic research studies for application in the population monitoring arena, for example. The emphasis, however, in this presentation is on the response component of dose-response in relation to cancer risk assessment.
The previous section on the multistage nature of the carcinogenic process provides the framework for considering tumor formation as a genetic process with gene mutations and alterations of chromosome structure and number generally being associated with phenotypic changes along the pathway. Thus, to develop biological information that can be used as input into tumor dose-response models, particularly for describing responses at levels below those at which the frequencies of tumors themselves can be accurately assessed, it is most appropriate to measure genetic endpoints.
A biomarker is a biological phenotype (eg, chromosome alteration, DNA adduct, speci c metabolite) that can be used to indicate a response at the cell or tissue level to an exposure. In this regard, it is generally a qualitative indicator of the potential for development of an adverse outcome such as cancer. A bioindicator is de ned as a cellular alteration that is proximate to the disease endpoint, such as a speci c mutation that is associated with tumor formation. Thus, a bioindicator can be perceived as informing directly on disease outcome in a quantitative way. We are beginning to identify potential bioindicators for cancer as more and more information is gained on the underlying mechanism of tumor formation for speci c tumor types. However, the relationship between bioindicator frequency and probability of cancer is yet to be established. Two examples might demonstrate this difference between biomarkers and bioindicators.
A atoxin B1 (AFB1) is considered to be a signi cant causative agent in hepatocellular carcinoma in regions with high presumed food contamination by AFB1. A unique mutational hotspot, a G to T transversion at the third base of codon 249 of the p53 gene, is observed in these tumors. Denissenko et al (8) showed that adducts at codon 249 were observed in HepG2 cells treated with AFB1, but this site was not notably sensitive to adduct formation. In addition, they observed that adducts at codon 249 were not repaired slowly. They suggested that AFB1 may not be involved in mutation at this speci c site or that an additional pathway such as combined infection with hepatitis B virus may be required for selection of codon 249 mutants in hepatocellular carcinoma. In this example, mutations at codon 249 of p53 might be a bioindicator of subsequent tumor development, but speci c DNA adduct formation in p53 or in total cellular DNA could be a biomarker of AFB1 exposure.
Cytogenetic alterations have been used for many years as biomarkers of exposure. The types of aberrations used, until relatively recently, are the so-called unstable aberrations, such as dicentrics and deletions. These chromosomal alterations are not per se indicators of adverse health outcome at the level of the individual analyzed. A recent large-scale study by Bonassi et al (6) has suggested that, as a group, individuals with the highest frequency of chromosomal alterations are at the greatest risk of developing cancer. This association cannot be placed in the context of exposure to known or suspected carcinogens. Thus, unstable chromosome aberrations can be used as biomarker of exposure and a biomarker of adverse health outcome. Recent developments with uorescence in situ hybridization (FISH) techniques have allowed for the PRESTON TOXICOLOGIC PATHOLOGY assessment of speci c translocations and other chromosomal events involved in speci c tumor formation. Thus, the assessment of one or more of these speci c chromome aberrations could be developed into a bioindicator of tumor outcome at the level of the individual. There is a need for the selection of both biomarkers and bioindicators of response that can be used in human population monitoring to quantitate the dose-response component of cancer risk assessment. Basic studies of the molecular events associated with exposure to speci c chemicals will aid in the selection of these informative biomarkers of response and bioindicators of disease.
QUANTITATING GENETIC ALTERATIONS Gene Mutations
A considerable amount of data has been generated on the quantitation of mutants and mutations in in vitro and in vivo situations (2) . In addition, the particular DNA alterations causing the mutant phenotype can be identi ed through DNA sequencing. These studies have led to a signi cant increase in knowledge of how speci c chemicals can induce mutations, and to the development of mutational spectra for speci c genes, following exposure to speci c chemicals. For the assessment of the frequency of induced mutations, the genes that have routinely been used are those that have selectable mutant phenotypes (HPRT, TK, and APRT). The value of such studies for providing a quantitative input into the doseresponse for cancer risk assessment is limited because none of the selectable loci are known or predicted to be involved in the formation of tumors.
There are a number of more recent techniques that have the potential for detecting mutations at unselected genetic loci. The challenge of detecting unknown mutations is signi cantly different from diagnostic testing for the presence of known mutations. At present the emphasis has been on the detection of mutations at hotspots or at loci known to be frequently mutated in human diseases, including cancer.
The best-characterized methods for detecting unknown mutations include ribonuclease cleavage, denaturing gradient gel electrophoresis, carbodiimide modi cation, chemical cleavage of mismatches, single-strand conformational polymorphism analysis, heteroduplex analysis, and sequencing of DNA (4). These methods involve chemical or enzymatic recognition of mismatches in DNA duplexes, electrophoretic separation of single-or double-stranded DNA, or sequencing, often of PCR products.
A recent method that appears to be well suited to the detection of somatic low abundance mutations in early cancer development uses a combination of rolling circle ampli cation (RCA) and PCR ligation detection reaction on a universal oligonucleotide microarray (19) . The ligated probes can be visualized by uorescence assessment and quantitated. RCA permits quanti cation of a single mutation from within a pool of 100 wild-type alleles.
Rolling-circle ampli cation can also be used to detect speci c mutations at the level of single cells within tissue samples (27) . Allele-discriminating oligonucleotide probes in conjunction with RCA has been used to discriminate wildtype and mutant alleles in the cystic brosis transmembrane conductance regulator, p53, BRCA-1, and Gorlin syndrome genes (27) .
These approaches provide ways to quantitate bioindicators of cancer in the form of speci c gene mutations at target sites.
Chromosomal Alterations
As mentioned before, the most signi cant advance in being able to quantitate chromosomal alterations of the types most frequently involved in tumors (ie, reciprocal translocations, inversions and aneuploidies) is the development of sophisticated FISH methods. The choice of uorescent probe allows for the detection of, for example, reciprocal translocations in toto, for selected chromosome pairs, speci c reciprocal translocations, speci c aneuploidies, including assessment in interphase cells, and all visible cytogenetic alterations using whole genome characterization or spectral karyotyping (26) . For speci c chromosomal translocations that have a clearly de ned break point, it is possible to use PCR-based methods to quantitate the frequency of the speci c translocation by breakpoint ampli cation (5) . The way forward with the approaches for quantitating bioindicators of cancer is to automate the process of detection; attempts are underway to do this (12) .
QUANTITATING GENE EXPRESSION Genomics
Until quite recently, gene expression in untreated or treated cells was assessed gene-by-gene, either at the transcription level using Northern blots or quantitative PCR or at the translation level using Western blots, for example. In the past few years, there has been a complete change in approach whereby microarrays of hundreds to thousands of genes can be used to assess mRNA levels over a range of cellular circumstances for a signi cant portion of the genome. A number of different technical approaches have been used, but for quantitative assessment of expression changes resulting from treatment with speci c chemicals or mixtures or as a result of genotypic changes such as those occurring during tumor progression, a 2-dye (or multi-dye) system seems to be the most informative. The advantage of a 2-dye system is that the cDNAs for comparison can be hybridized to the same microarray. The pattern of uorescence provides information on enhanced, reduced, or unaltered expression levels in a treated sample, for example, versus an untreated sample of the same cell type. Some general discussion of the current state of the eld can be found in the review by Kallioniemi (17) and the commentary by He and Friend (15) .
Although it is dif cult to fully review the state of the eld of genomics in this short overview, 2 recent studies serve to highlight the impact that microarray analysis can have in the eld of cancer research. In addition, these studies demonstrate how microarray analysis can lead to the selection of informative bioindicators of response that can be used in dose-response characterization in cancer risk assessment.
Dong et al (9) used differential display and cDNA microarray to identify changes in gene expression with transformation and metastasis in a squamous cell carcinoma model. Differential display was used to identify candidate genes that were expressed primarily in transformed and metastatic cells and these were selected and cloned. Northern blot analysis was used to con rm the differential expression of these genes.
Those genes that were con rmed as being differentially expressed were included in a microarray analysis of some 4,000 elements. About three quarters of the genes identi ed by differential display and con rmed by Northern analysis showed altered expression by microarray. A cluster analysis approach was used to identify genes that were differentially expressed by either or both differential display and microarray analysis. The broad conclusion was that early response genes related to NF-j B contribute to metastatic tumor progression. This study shows very elegantly how genomic approaches can be used to characterize changes involved in tumor formation.
A study by Hedenfalk et al (16) demonstrated that microarray and tissue array techniques could be used to differentiate between breast cancers involving mutations in BRCA1 or BRCA2 and between both genotypes and tumors that were sporadic in nature. The value is to be able to identify speci c tumor classes based on their gene expression pattern, and to identify potential bioindicators of tumor outcome.
These two examples highlight the interpretation of data from targeted studies. However, there remains a concern that microarray analysis can generate vast quantities of data but that interpreting these in a valid way is dif cult at best. This is a valid concern. The parallel development of statistical approaches for interpreting the array data has to take place. Two recent publications attest to the sophisticated approaches that are being developed. Alter et al (3) describe a method based on singular value decomposition, and Burke (7) presents a simplifying approach based on discovering patterns in microarray data. It is anticipated that progress in the collection and analysis of microarray data will be very rapid.
Proteomics
To understand the phenotypes of cells, it is necessary to know about proteins-amounts and changes in structure, for example. The eld of proteomics is the study of a cell's protein pro le and like genomics is expanding very rapidly. However, being able to study a cell's total protein pro le, in a way similar to that for mRNA pro ling described previously, represents a challenge because protein characterization lags somewhat behind DNA/RNA characterization for technical reasons, as much as for any other reason.
Current approaches to quantitative assessment of protein levels in cells of different types or under different treatment conditions involve a combination of 2D-gel electrophoresis identi cation and mass spectrometry characterization and quantitation. A promising approach is described by Aebersold et al (1) . The rationale is to differentially tag proteins from two different cell samples using isotope coded af nity tags (ICAT) that bind to cysteines. The ICATs exist in 2 forms, isotopically heavy and isotopically light, such that one cell sample is labeled with the heavy ICAT and one with the light ICAT. After ICAT treatment the cell samples are mixed, and the sample treated to enrich for low abundance proteins. The combined sample is proteolyzed and the ICAT-tagged peptides are separated and analyzed by microcapillary HPLC-ESI-MS/MS. The relative ion intensities of 2 differentially tagged forms of a speci c peptide indicate their relative abundance. The protein from which the peptide originated is then identi ed by searching a sequence database with the recorded MS/MS spectrum. This sophisticated approach provides a relative quantitation for cellular proteins in treated versus untreated cells or transformed versus normal cells, for example.
CONCLUSIONS
The requirement for quantitative cancer risk assessment and for assessing the impact of regulations arising from risk management strategies on public health is to be able to identify disease outcomes at low frequencies in the population or at low levels of exposure to environmental agents. To do this, there is a need to select informative bioindicators of disease so that estimates of disease outcome can be made for conditions when the disease outcome itself cannot be assessed, generally for reasons of sensitivity of detection. The present commentary addresses current approaches for selecting such informative bioindicators, particularly as applied to cancer. The basis for such bioindicator selection is that tumor development involves changes in genotype (gene mutations, chromosomal alterations) and changes in gene expression patterns (mRNA and protein). The pathway from a normal cell to a metastatic tumor involves a number of essential cellular alterations and a very large number of ancillary ones. The challenge is to link essential changes to the complex phenotypes that constitute tumors and preneoplastic lesions in a qualitative and ultimately a quantitative way.
